Shares of Gilead Sciences Inc. GILD, -3.11% rose more than 5% in the extended session Thursday after the pharma company reported fourth-quarter earnings and sales above Wall Street expectations, sayin...
Tag: Gilead
GILD Stock: Gilead Posts Its Best Growth In 7 Years As Cancer Drug Sales Rocket
Gilead Sciences (GILD) crushed fourth-quarter expectations Thursday and issued an unexpectedly bullish outlook that buoyed GILD stock. X The company hasn’t seen growth this strong since 2015 at ...
Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of Earnings
IBD’s Income Investor highlights top dividend stocks. This week, we look at Gilead Sciences (GILD) as the drug giant nears a buy point amid continued stability and a growing dividend. X Gilead ...
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug
Shares of Arcus Biosciences Inc. RCUS, -27.76% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that...
Gilead Sciences, Moderna, Tesla and more
A sign is posted in front of the Gilead Sciences headquarters on April 29, 2020 in Foster City, California. Justin Sullivan | Getty Images Check out the companies making the biggest moves midday: Gene...
IPO Stock Arcellx Breaks Out On $325 Million Cancer Deal With Gilead
Recent initial public offering Arcellx (ACLX) forged a $325 million multiple myeloma deal with Gilead Sciences (GILD) on Friday, and the IPO stock broke out. X The news comes in lockstep with promisin...
GILD Stock Surges: Why Gilead Sees Its Oncology Business As A Force To Be Reckoned With
Gilead Sciences‘ (GILD) first-in-class cancer drug and GILD stock are finally hitting their stride. X The biotech company is an expert in a means of battling cancer by reprogramming a patient...
Should I buy Gilead Sciences shares in November 2022?
Gilead Sciences, Inc. (NASDAQ: GILD) shares have advanced from $61.45 to $80 since the beginning of October 2022, and the current price stands at $79.46. Gilead Sciences reported better-than-expected ...
Analysts Turn Bullish On Gilead After Q3 Earnings Surpass Expectations
Thursday, Gilead Sciences Inc (NASDAQ: GILD) reported Q3 revenue decreased 5% Y/Y to $7.04 billion, which beat average analyst estimates of $6.12 billion. The company reported quarterly earnings of $1...
Gilead stock is not out of room to run just yet: Truist
Gilead Sciences Inc (NASDAQ: GILD) ended this week up nearly 20% after reporting its quarterly results that handily topped Street estimates and subsequently winning an upgrade from a Truist analyst. G...
GILD Stock: With A Breakout On The Line, Gilead Reports Massive Cancer Drug Sales
Gilead Sciences (GILD) crushed third-quarter expectations Thursday as sales of its cancer drugs nearly doubled. The results prodded GILD stock higher. X The bullish report follows recent approvals for...
Gilead stock price ‘does not’ reflect its oncology business: Analyst
Gilead Sciences Inc (NASDAQ: GILD) ended in the green on Tuesday after a JPMorgan analyst turned bullish on the biopharmaceutical company. Gilead stock should be worth $80 a share Chriss Schott now ra...
GILD And BMY Offer A Haven In A Turbulent Market
Following another ugly market week, the average U.S. stock is now trading in Bear Market territory. Of course, such was also the case in 2020 and 2018 and 2016 and more than a few other periods throug...
Bristol-Myers Squibb, Twitter, Gilead Sciences and more
Check out the companies making the biggest moves midday Monday: Gilead Sciences — Shares of Gilead rose 3.8% after the biopharmaceutical company revealed it settled a patent case over its HIV therapie...
Sam Jaeger Talks Religion, Gilead And Cults As Two Series Premiere In September
Sam Jaeger as Peter Mathis in ‘Devil in Ohio’ on Netflix. PHOTO COURTESY OF NETFLIX. Extreme religious fundamentalism is the throughline of two series starring Sam Jaeger. Both are based o...
Gilead Sciences, CVS, Electronic Arts and more
A customer walks towards the entrance of a CVS Health Corp. store in downtown Los Angeles, California, U.S., on Friday, Oct. 27, 2017. Christopher Lee | Bloomberg | Getty Images Check out the companie...
Gilead Sciences Shares Cross 5% Yield Mark
In trading on Tuesday, shares of Gilead Sciences were yielding above the 5% mark based on its quarterly dividend (annualized to $2.92), with the stock changing hands as low as $57.16 on the day. Divid...
Now’s The Time For Low-Debt Stocks Like Gilead And These 3 Others To Pay Off
Deborah Birx, coronavirus response coordinator, and United States Secretary of Health and Alex Azar, … [+] secretary of Health and Human Services (HHS), smile during a meeting with Daniel O̵...
Should I buy Gilead Sciences shares in May 2022?
Gilead Sciences, Inc. (NASDAQ: GILD) shares have weakened from $72.27 to $57.19 since the beginning of January 2022, and the current price stands around $59.39. Gilead Sciences reported better than ex...
Should I buy Gilead Sciences shares after strong Q4 results?
Gilead Sciences, Inc. (NASDAQ: GILD) shares remain under pressure even though the company reported strong fourth-quarter results last trading week. Gilead has increased quarterly dividend Gilead Scien...